Welcome to our dedicated page for Qiagen news (Ticker: QGEN), a resource for investors and traders seeking the latest updates and insights on Qiagen stock.
QIAGEN N.V. develops Sample to Insight technologies for extracting, purifying, amplifying and interpreting DNA, RNA and proteins. Its recurring news covers life sciences and molecular diagnostics applications, including sample technologies, assay technologies, bioinformatics and laboratory automation used in clinical healthcare, pharmaceutical research, academia, forensics and other research settings.
Company updates frequently address product and regulatory developments across QuantiFERON tuberculosis testing, QIAstat-Dx syndromic testing panels, QIAcuity digital PCR, QIAGEN Digital Insights and automated sample-preparation systems such as QIAsymphony and QIAstat-Dx Rise. Financial news also tracks sales trends across consumables, instruments and services, profitability measures, capital-return actions, acquisitions, and changes affecting portfolio growth areas.
QIAGEN (NYSE: QGEN) received U.S. FDA clearance to run all QIAstat-Dx Gastrointestinal (GI) Panels on the fully automated QIAstat-Dx Rise platform, expanding the system's menu to consolidate respiratory and GI syndromic testing.
The high-throughput Rise supports up to 160 tests per day, ~1-hour results and <1 minute hands-on time, and this marks the ninth FDA clearance for QIAstat-Dx in 24 months.
Parse Biosciences (NYSE: QGEN) launched Evercode Whole Transcriptome v4, a new single-cell RNA-seq chemistry shipping March 2026 that increases sensitivity, scalability and cell recovery.
Key metrics: supports up to 5 million cells and 384 samples per run, boosts gene detection while requiring fewer reads, and raises cell recovery by up to 75%. Webinar: March 3, 2026 at 9:00 AM Pacific.
QIAGEN (NYSE: QGEN) reported Q4 2025 net sales of $540 million (+4% actual, +1% CER) and adjusted diluted EPS of $0.62, ahead of outlook. Full-year 2025 net sales were $2.09 billion (+6% actual, +5% CER) and adjusted diluted EPS $2.40 CER.
Growth pillars delivered $1.49 billion CER (+8% CER) and adjusted operating margin rose to 29.5%, up 80 bps. QGEN returned > $1.1 billion to shareholders, completed Parse and Genoox bolt-ons, and guided 2026 net sales growth of at least 5% CER with adjusted diluted EPS of at least $2.50 CER.
QIAGEN (NYSE:QGEN) unveiled QIAsprint Connect, its first high-throughput benchtop automation system, at SLAS 2026. The compact system processes up to 192 samples per run, offers customizable protocols, a touch-based UI, and sustainability-focused consumables that cut plastic use by up to 50% and packaging by 40%.
QIAGEN also highlighted QIAsymphony Connect for clinical DNA/RNA extraction and QIAmini for low-throughput labs. QIAsprint Connect will be shown live on Feb 9, 2026 at 2:30 p.m. EST.
QIAGEN (NYSE: QGEN) appointed Mark Stevenson as an independent member of the Supervisory Board effective January 23, 2026; he will stand for election at the Annual General Meeting in June 2026. On the same date, Prof. Dr. Ross Levine stepped down from the Supervisory Board following his appointment as Chief Scientific Officer at Memorial Sloan Kettering Cancer Center and will continue as Chair of QIAGEN’s Scientific Advisory Board. Mark Stevenson brings more than 30 years of life‑science operational leadership, most recently as EVP & COO at Thermo Fisher Scientific, and previously as President & COO at Life Technologies and Applied Biosystems. He is an Operating Partner at Fivespan Partners and a board member of Ingersoll Rand. The Supervisory Board now comprises eight members, including Stevenson.
QIAGEN (NYSE: QGEN) will release fourth-quarter 2025 results on Wednesday, February 4, 2026 shortly after 22:05 Frankfurt / 21:05 London / 16:05 New York. A conference call to discuss results is scheduled for Thursday, February 5, 2026 at 15:30 Frankfurt / 14:30 London / 09:30 New York. Investors can join via callback registration, dial-in phone numbers (U.S. +1 646 769 9200; UK +44 (0)20 7769 6464; GER +49 (0)69 254 99300) using Conference ID 3382302, or the live audio webcast. The live service opens 15 minutes before the call; a replay will be available at the provided webcast replay link.
QIAGEN (NYSE: QGEN) set 2026 priorities across five growth pillars — Sample technologies, QIAstat-Dx, QIAcuity, QIAGEN Digital Insights (QDI) and QuantiFERON — to support a goal of at least $2.0 billion combined annual pillar sales in 2028.
Key facts: QIAGEN completed the acquisition of Parse Biosciences and expects ~$40 million in Parse sales in 2026; cumulative placements: QIAstat-Dx >5,200, QIAcuity >3,200. 2026 product plans include three sample prep systems (QIAsymphony Connect, QIAsprint Connect, QIAmini), BCID panel submissions for U.S. clearance and CE-IVDR, expanded QIAcuity assays and AI-enabled QDI offerings. QuantiFERON updates aim to increase throughput up to 75% more patients/hour and deliver results 25% faster on partner platforms.
QIAGEN (NYSE: QGEN) will complete a synthetic share repurchase of approximately $500 million combining a direct capital repayment with a reverse stock split, effective with the last pre-consolidation trading day on January 7, 2026.
Every 20 pre-consolidation shares will be consolidated into 19, reducing issued shares by about 10.9 million from 217.7 million, or roughly a 5% reduction. Following consolidation the company will repay $2.29 per pre-consolidation share from existing cash reserves. QIAGEN says this completes deliveries toward its commitment to return at least $1 billion to shareholders by end-2028 and that additional return measures are under consideration for 2026 and beyond.
QIAGEN (NYSE: QGEN) introduced QIAsymphony Connect at AMP 2025 and began an early access program ahead of a planned full commercial release in mid-2026. The platform builds on >3,000 cumulative placements of the prior generation (end-2024) and promises improved extraction, up to 50% higher throughput in specific liquid biopsy protocols, 2D barcode traceability, LIMS and QIAsphere connectivity, and optimization for high-sensitivity oncology workflows like MRD monitoring.
At AMP, QIAGEN highlighted Sample to Insight CGP workflows with Element Biosciences Trinity technology and a partnership with Myriad Genetics on an HRD assay; early-access data and planned commercial launches are targeted for early 2026 (commercial launch excluding Japan).
QIAGEN (NYSE: QGEN) reported Q3 2025 net sales of $533 million (+6% at actual rates) and adjusted diluted EPS of $0.61, above its outlook. The company raised its FY2025 adjusted diluted EPS target to about $2.38 CER (from $2.35) and reaffirmed net sales growth of about 4–5% CER (core sales ~5–6% CER). Q3 adjusted operating income margin remained strong near 29.6% and operating cash flow was $165 million.
QIAGEN announced the acquisition of Parse Biosciences to enter the single-cell market and approved a $500 million synthetic share repurchase to be completed in January 2026. The CEO will transition after a successor is appointed.